Alize Pharma Sas

Asta Medica, Aktiengesellschaft

Pierrel Spa

Millendo Therapeutics Sas

Alize Pharma

Ezio Ghigo

Aart Jan Van Der Lely

Piero Del Soldato

Maria Felice Brizzi

Giampiero Muccioli

Riccarda Granata

Franklin M Boghen

Franco Camanni

Eugenio Muller

Gianpiero Muccioli

Mauro Papotti

Romano Deghenghi

The present invention relates to a method for treating a cardiovascular disease, for increasing the number of circulating angiogenic cells (CAC) and/or improving the function of CAC and a method for improving vascular remodeling and/or neovascularisation. The method comprises administering to the subject a therapeutically effective amount of unacylated ghrelin or a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1 or a fragment or analog thereof having the biological activity of SEQ ID NO: 1; and to pharmaceutical compositions comprising unacylated ghrelin or a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1 or a fragment or analog thereof having the biological activity of SEQ ID NO: 1.

Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease

An isolated polypeptide comprising any amino acid fragment of unacylated ghrelin or any analog thereof, wherein the polypeptide has an activity selected from the group consisting of a) decreasing blood glucose levels; b) increasing insulin secretion an/or sensitivity; c) binding to insulin-secreting cells; and d) promoting survival of insulin-secreting cells. As well as the use of the polypeptide in the treatment of a disorder associated with impaired glucose metabolism.

Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders

The present invention relates to compositions containing unacylated ghrelin and derivatives thereof and their uses in the control of glycemia in ageing patients, GH deficient patients, diabetic patients and obese patients.

Methods for promoting growth and survival of insulin-secreting cells

A novel combination of ghrelin and unacylated ghrelin is described herein. Methods of administering and uses of this combination to alter an insulin-associated parameter are also described. Compositions and packages containing ghrelin and/or one of its analogs and nonacylated ghrelin and/or one of its analogs as well as the uses of such compositions in providing therapeutic benefit to human patients diagnosed with for example insulin resistance, diabetes and obesity are described.

Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance

Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof

A method for treating a tumor in a mammal by administering a growth hormone releasing compound or an antagonist thereof in an amount effective to reduce or inhibit proliferation of tumorigenic cells in the mammal. In particular, the tumors to be treated include lung, mammary, thyroid or pancreas tumors. The preferred compounds are certain peptides that contain methyl tryptophan and lysine units.

Treatment of tumors by administration of growth hormone releasing

A pharmaceutical composition for intranasal administration comprising GHRH, a cholinergic agonist and in case a bile salt, suitable for the treatment of growth disorders and for use in the diagnosis of GH hypophyseal functionality.

Pharmaceutical composition for intranasal administration, comprising

Growing community of inventors

Turin, Italy

Ezio Ghigo